91 results
8-K
EX-99.1
NVCR
NovoCure Ltd
2 May 24
Novocure Reports First Quarter 2024 Financial Results
7:01am
. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Exhibit 99.1
NOVOCURE LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS
8-K
EX-99.1
rh27aer192egg1 wan
27 Mar 24
Regulation FD Disclosure
7:00am
8-K
EX-99.1
04uchjsvc2
22 Feb 24
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
7:06am
8-K
EX-99.1
1nvtv695qbx oiso7y
18 Jan 24
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
7:01am
8-K
EX-99.1
kjgziww9 wfhc6jkxdl
9 Jan 24
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
7:00am
8-K
EX-99.1
99zxq1y2w0jsrb98
8 Jan 24
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
7:10am
8-K
EX-99.1
8t2hx07 yvllnt0v
4 Jan 24
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
4:10pm
8-K
EX-99.1
1j88y33e6t31nkxzn
28 Nov 23
Regulation FD Disclosure
7:30am
8-K
EX-99.1
mqgklefw
26 Oct 23
Novocure Reports Third Quarter 2023 Financial Results
7:03am
8-K
EX-99.1
47q kr8x7r
28 Aug 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
2m9u5rd7zy 3x
27 Jul 23
Novocure Reports Second Quarter 2023 Financial Results
7:03am
8-K
EX-99.1
r6qnxh8tc
21 Jul 23
Regulation FD Disclosure
8:00am